https://www.mercurynews.com/2021/10/26/covid-fda-expert-panel-blesses-vaccine-for-kids-5-11/

A panel of medical experts advising the U.S. Food and Drug Administration concluded Tuesday that the benefits of vaccinating 5-11 year-old children with Pfizer’s COVID-19 vaccine at a third of the dosage given teens and adults outweighs the risks of rare but potentially dangerous side effects like heart inflammation.

The FDA’s Vaccines and Related Biological Products Advisory Committee’s decision is a key step in authorizing the shots for elementary school-aged children. Its recommendations aren’t binding but are typically followed by the FDA. The Centers for Disease Control and Prevention’s advisory committee is expected to consider the matter Nov. 2-3 and authorization could follow soon after.